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background
 
The treatment of infants with bronchiolitis is largely supportive. The role of bronchodila-
tors is controversial. Most studies of the use of bronchodilators have enrolled small num-
bers of subjects and have examined only short-term outcomes, such as clinical scores.
 
methods
 
We conducted a randomized, double-blind, controlled trial comparing nebulized single-
isomer epinephrine with placebo in 194 infants admitted to four hospitals in Queens-
land, Australia, with a clinical diagnosis of bronchiolitis. Three 4-ml doses of 1 percent
nebulized epinephrine or three 4-ml doses of normal saline were administered at four-
hour intervals after hospital admission. Observations were made at admission and just
before, 30 minutes after, and 60 minutes after each dose. The primary outcome measures
were the length of the hospital stay and the time until the infant was ready for discharge.
The secondary outcome measures were the degree of change in the respiratory rate, the
heart rate, and the respiratory-effort score and the time that supplemental oxygen was
required.
 
results
 
There were no significant overall differences between the groups in the length of the
hospital stay (P=0.16) or the time until the infant was ready for discharge (P=0.86).
Among infants who required supplemental oxygen and intravenous fluids, the time un-
til the infant was ready for discharge was significantly longer in the epinephrine group
than in the placebo group (P=0.02). The need for supplemental oxygen at admission had
the greatest influence on the score for severity of illness and strongly predicted the length
of the hospital stay and the time until the infant was ready for discharge (P<0.001). There
were no significant changes in the respiratory rate, blood pressure, or respiratory-
effort scores from before each treatment to after each treatment. The heart rate was sig-
nificantly increased after each treatment with epinephrine (P=0.02 to P<0.001).
 
conclusions
 
The use of nebulized epinephrine did not significantly reduce the length of the hospital
stay or the time until the infant was ready for discharge among infants admitted to
the hospital with bronchiolitis.
abstract
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cute viral bronchiolitis is the
 
most common lower respiratory tract in-
fection in the first year of life; approxi-
mately 1 percent of healthy infants are hospital-
ized with this infection annually.
 
1,2
 
 It is generally
a self-limiting condition and is most commonly
associated with respiratory syncytial virus infection.
It is characterized by bronchiolar obstruction due
to edema, with accumulation of mucus and cellular
debris.
 
3
 
 The treatment of infants with bronchioli-
tis has been largely supportive, with supplemental
oxygen, minimal handling of the infant, and the use
of intravenous fluids or ventilatory support where
necessary. The role of bronchodilators is controver-
sial. The recent Cochrane Review of the use of bron-
chodilators for bronchiolitis showed short-term im-
provement in clinical scores, with no improvement
in measures of oxygenation or in the rate of hospi-
talization.
 
4
 
Wohl and Chernick postulated that, since mu-
cosal edema was an important component of air-
way obstruction in infants with bronchiolitis, a log-
ical approach to therapy might be to use a combined
 
a
 
-adrenergic and 
 
b
 
-adrenergic agonist, such as epi-
nephrine.
 
3
 
 Eleven trials of epinephrine in bronchi-
olitis have been reported. One was an uncontrolled
trial in patients undergoing ventilation.
 
5
 
 Ten tri-
als were conducted in patients not undergoing ven-
tilation; 6 of the 10 compared epinephrine with
albuterol,
 
6-11
 
 and 4 compared epinephrine with pla-
cebo.
 
12-15
 
 In most studies, epinephrine was admin-
istered by nebulizer, although some studies used
parenteral administration.
 
9,14
 
 The doses ranged
from 0.5 mg
 
6
 
 to approximately 8 mg.
 
11
 
 Most stud-
ies measured changes in clinical scores; seven used
pulse oximetry
 
5-9,12,13
 
; and four measured pulmo-
nary mechanics.
 
5,10,11,15
 
 Only one study reported
the length of the hospital stay
 
6
 
; however, that study
involved only 30 patients and may have been un-
derpowered. Most studies reported some improve-
ment in short-term outcomes, although the condi-
tion of a few patients worsened, as measured by
clinical scores,
 
10
 
 pulmonary mechanics,
 
5
 
 or oximet-
ric findings
 
7
 
 after they received epinephrine.
We conducted a large, multicenter, randomized,
double-blind, placebo-controlled study to examine
the effect of nebulized epinephrine on the length of
the hospital stay among infants with bronchiolitis.
Infants less than 12 months of age (or less than 12
months of corrected age if they were premature)
who were admitted to any of four Queensland, Aus-
tralia, hospitals (Royal Children’s Hospital, Gold
Coast Hospital, Caboolture Hospital, and Redcliffe
Hospital) between April 2000 and September 2001
with a first episode of wheezing requiring hospital-
ization and with a clinical diagnosis of bronchioli-
tis were considered for entry into the study. A clin-
ical diagnosis of bronchiolitis was made if the infant
had a history of upper respiratory tract infection
and clinical findings consistent with bronchiolitis,
including wheezing or wheezing with crackles and
respiratory distress with chest recession. Infants
with cardiac disease or clinically significant respira-
tory disease, such as cystic fibrosis, were not eligi-
ble, although infants with chronic neonatal lung
disease associated with prematurity were included.
Infants were excluded if they had received cortico-
steroids in any form within 24 hours before pres-
entation or had received bronchodilators within
4 hours before presentation. Infants who required
ventilatory support before their parents could give
consent for their participation in the study were not
eligible. After written informed parental consent had
been obtained, the infants were randomly assigned
to receive three doses of nebulized single-isomer
epinephrine or placebo at 4-hour intervals within
24 hours after their admission to the hospital.
Randomization was performed by the pharma-
cy at the Princess Margaret Hospital in Perth, Aus-
tralia, which manufactured the treatment packag-
es. Randomization was stratified according to center
in blocks of 50 numbers, so that each block com-
prised 25 patients randomly assigned to epineph-
rine and 25 to placebo. Two of the smaller hospi-
tals, Caboolture and Redcliffe, were regarded as one
center for the purpose of stratification. Each patient
was assigned the next sequential number for the
particular center. There was one bottle of epineph-
rine or placebo solution per patient randomly as-
signed to a treatment group, corresponding to the
patient’s number. Interim analysis was performed
by the study statistician, as requested by the Royal
Children’s Hospital ethics committee, after the first
50 patients from the Royal Children’s Hospital had
undergone randomization. The absence of a finding
of superiority in the interim analysis was communi-
cated solely to the principal investigator and the eth-
ics committee. Except for the interim analysis, the
allocation codes were not opened until the trial was
completed.
All children admitted to Royal Children’s, Gold
Coast, Caboolture, and Redcliffe hospitals with
bronchiolitis were treated according to the same
a
methods
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clinical pathway to ensure consistent care and min-
imize the variability of the results. The length of the
hospital stay may have been affected by many ad-
ministrative and social factors unrelated to the con-
dition of the child. Therefore, we recorded another
measure of efficacy: the time until the child was
ready for discharge. An infant was considered ready
for discharge if he or she had not received supple-
mental oxygen for 10 hours, had minimal or no
chest recession, and was feeding adequately, with-
out the need for intravenous fluids. The clinical
pathway included guidelines for the use and termi-
nation of supplemental oxygen and the use of intra-
venous fluids, although the treating physicians were
free to use supplemental oxygen or intravenous flu-
ids as they thought appropriate. The criterion for
supplemental oxygen was less than 94 percent oxy-
gen saturation or any combination of clinically sig-
nificant respiratory distress, a respiratory rate above
60 per minute, and difficulty in feeding. The use of
supplemental oxygen was terminated when the ox-
ygen saturation was consistently above 93 percent
or when the infant’s condition had been stable for
four hours and he or she was starting to tolerate
oral feeding.
The guidelines suggested that infants should
receive intravenous fluids rather than oral feeding
if supplemental oxygen was required and the respi-
ratory rate was above 60 per minute, or if oral feed-
ing was deemed inadequate. Comfort feeding was
allowed. The use of intravenous fluids was termi-
nated when the infant was able to tolerate oral feed-
ing. Data were also collected on variations in the
clinical pathway, including the use of other drugs
during hospitalization. Data on readmission to the
hospital in the month after discharge were also col-
lected.
Each infant was assigned one amber bottle con-
taining 15 ml of clear, colorless solution with an
odor of chlorobutanol, containing either epineph-
rine (epinephrine acid tartrate, 1 percent, with so-
dium metabisulfite and vehicle), or vehicle (chloro-
butanol, edetate disodium, sodium chloride, and
purified water); the contents were sufficient for
three doses of 4 ml, with some margin for spillage.
A nasopharyngeal-aspiration sample was ob-
tained routinely from all patients for detection of
respiratory syncytial virus. The admitting medical
officer and nurse recorded detailed clinical histo-
ries in the clinical pathway, including the duration
of symptoms before presentation at the hospital,
the medical history, the infant’s ability to feed, cur-
rent and previous medications, immunization rec-
ord, parental smoking history, and family history
of atopy. Observations at admission included respi-
ratory rate and heart rate while the infant was quiet,
temperature, respiratory effort, oxygen saturation
while breathing room air, presence or absence of
wheezing or crackles on auscultation of the chest,
and level of hydration. The respiratory rate, meas-
ured over a period of 30 seconds, was scored by com-
parison with data on age-matched normal infants.
 
16
 
Each infant’s condition was classified as mild, mod-
erate, or severe according to a severity score calculat-
ed from the oxygen saturation, respiratory rate, and
respiratory effort observed at admission (Table 1).
Epinephrine and placebo were administered by
means of standard hospital jet nebulizers through
a firmly applied face mask with an oxygen flow of
6 liters per minute. MicroMist (Hudson RCI) with an
Aerflo mask (Maersq Medical) was used at Cabool-
ture Hospital, Misty-Neb AirLife (Baxter) with an
Aerflo mask at Redcliffe Hospital, Sidestream Med-
ic-Aid (Niche Medical UK) with a Medic-Aid pedi-
atric mask at Gold Coast Hospital, and MicroMist
with an Aerosol Mask (Hudson RCI) at Royal Chil-
 
Table 1. Calculation of the Severity Score.
Respiratory-effort score
 
The nurse examined the patient for intercostal recession, subcostal recession, 
substernal recession, tracheal tug, and nasal flaring and assigned a score 
of 0 (not present), 1 (mild to moderate), or 2 (severe) for each factor. Each 
score was then multiplied by a weighting factor, as follows: intercostal re-
cession (¬1), subcostal recession (¬1), substernal recession (¬1), tracheal 
tug (¬1.5), and nasal flaring (¬1.5). The weighted scores were then totaled 
to obtain a score for respiratory effort. Finally, infants with respiratory-effort 
scores of 0 to 4.9 were given a severity score of 1 (mild); those with respi-
ratory-effort scores of 5.0 to 8.9 were given a score of 2 (moderate); and 
those with respiratory-effort scores of 9.0 to 12.0 were given a score of 
3 (severe).
 
Oxygen saturation breathing ambient air
 
The infants received scores of 0, 1, or 2 for oxygen-saturation values of 95 
to 100 percent, 90 to 94 percent, and less than 90 percent, respectively.
 
Respiratory rate compared with that of healthy infants of the same age
 
Those whose rates were within 2 SD of the mean for their age received a score 
of 0; those whose rates were 2 to 3 SD above or below the mean for their 
age received a score of 1; and those whose rates were more than 3 SD from 
the mean for their age received a score of 2.
 
Overall severity score
 
The above three scores were totaled for each infant, and the infant’s condition 
was classified as mild (total score less than 2), moderate (total score 2 to 3), 
or severe (total score more than 3).
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dren’s Hospital. The same types of nebulizer bowls
and masks were used throughout the study at each
hospital. The nursing staff recorded the respiratory
and heart rates while the patient was quiet, supple-
mental oxygen requirements, oxygen saturation, res-
piratory effort (scoring each component as mild,
moderate, or severe), and blood pressure just be-
fore and 30 and 60 minutes after the delivery of
the drug.
The two primary outcomes were the length of
the hospital stay and the time until the infant was
ready for discharge. The secondary outcomes were
changes in the components of the clinical scores
before and after nebulization therapy and the time
that supplemental oxygen was required.
 
ethics
 
The study was approved by the ethics committees
of all four centers. Written informed consent was
obtained for each infant from a parent.
 
estimate of sample size
 
Calculation of power was difficult, because no ac-
curate data were available for this group of patients
on the standard deviation of the length of the hos-
pital stay or the length of time receiving supplemen-
tal oxygen. We therefore specified that we aimed
to detect a difference between the two groups of
half a standard deviation in the length of the hos-
pital stay and the time until the infant was ready for
discharge at the 1 percent significance level for a
two-sided test with 85 percent power; this would
require 200 infants, with 100 infants in each group.
 
statistical analysis
 
The data from all randomized patients were ana-
lyzed on an intention-to-treat basis. The differences
between the treatment groups in the characteris-
tics of the patients were assessed by Fisher’s exact
test and the Mann–Whitney test with exact proba-
bilities. Between-group comparisons of the length
of the hospital stay, the time until the infant was
ready for discharge, and the length of time receiv-
ing supplemental oxygen were performed by analy-
sis of variance after appropriate logarithmic trans-
formation to correct for skewness. Time receiving
oxygen was analyzed as a conditional variable, since
not all infants required oxygen. The analysis was
performed with SPSS software (standard version
10). One-way analysis of variance was used for a
simple comparison between the two randomized
groups. Means and 95 percent confidence intervals
were back-transformed from log to linear scales for
presentation. The treatment differences and their
confidence intervals were also back-transformed
from log to linear scales to calculate the ratio of
the results with epinephrine to the results with pla-
cebo. To adjust this comparison, the effects of co-
variates were screened with use of general linear
modeling. The covariates, which were assessed at
admission, before randomization, were the hospi-
tal at which the infant was treated, the severity score,
and the use or nonuse of supplemental oxygen, with
or without the use of intravenous fluids. Both the
use of supplemental oxygen, with or without the
use of intravenous fluids, and its interaction with
the treatment group were significant (P<0.05), but
other covariates and their interactions were not
significant. Hence the treatment comparison was
also performed separately according to the use or
nonuse of supplemental oxygen and intravenous
fluids, with pooled variance for each comparison.
There was no interaction between the severity score
and treatment, nor was severity a significant covari-
ate when the use of supplementary oxygen, with or
without the use of intravenous fluids, was included
in the model. All reported P values are two-sided.
A total of 194 infants were assigned to treatment:
99 to epinephrine and 95 to placebo. There were no
significant differences between the groups at ran-
domization in terms of demographic variables, the
proportion of infants requiring supplemental ox-
ygen or intravenous fluids, or the proportion of in-
fants whose nasopharyngeal aspirate was positive
for respiratory syncytial virus (Table 2). There were
no significant differences at admission between the
groups in the duration of wheezing (P=0.16) or
the duration of coryza (P=0.35) (Table 2).
 
primary end points
 
Treatment with epinephrine had no significant ef-
fect on the length of the hospital stay (P=0.16) or
the time until the infant was ready for discharge
(P=0.86). The ratio of the length of the hospital stay
in the epinephrine group to that in the placebo
group was 0.85 (95 percent confidence interval,
0.67 to 1.07). The ratio of the time until ready for
discharge in the epinephrine group to that in the
placebo group was 0.98 (95 percent confidence in-
terval, 0.74 to 1.29) (Table 3). The length of the hos-
pital stay for the epinephrine group ranged from
results
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10 to 443 hours, with an interquartile range of 26
to 116 hours. The range for the placebo group was
13 to 438 hours, with an interquartile range of 42
to 111 hours. In the epinephrine group, the time
until the infant was ready for discharge ranged from
7 to 398 hours, with an interquartile range of 21
to 101 hours. The range in the placebo group was
8 to 380 hours, with an interquartile range of 21
to 95 hours. The need for supplemental oxygen,
with or without intravenous fluids, had by far the
greatest influence on the severity-of-disease rank-
ing (P<0.001) and strongly predicted the length of
the hospital stay (Fig. 1). Among infants requiring
both supplemental oxygen and intravenous fluids,
the time until the infant was ready for discharge in
the epinephrine group (135.9 hours; 95 percent
confidence interval, 96.6 to 191.3) was significantly
longer than that in the placebo group (80.2 hours;
95 percent confidence interval, 62.0 to 103.5; P=
0.02). The differences between the epinephrine and
placebo groups in the length of the hospital stay
and the time until ready for discharge were not sig-
nificant for infants who received no oxygen or ox-
ygen without intravenous fluids (P=0.06 to P=0.39)
(Table 3). The difference between the length of the
hospital stay and the time until the infant was ready
for discharge was significantly greater in the place-
bo group than in the epinephrine group (P=0.03).
 
secondary end points
 
There was no significant difference between the
groups in the time receiving supplemental oxygen
(Table 3). Seven infants (3.6 percent) required ad-
mission to the intensive care unit, and three (1.5
percent) required ventilatory support. There were
no significant differences between the groups in the
proportions requiring intensive care (P=0.23) or
ventilatory support (P=0.08).
Three patients were readmitted to the hospital
within one month after discharge (two in the place-
bo group and one in the epinephrine group). Four-
teen infants did not receive all three doses of nebu-
lized epinephrine or placebo (10 in the epinephrine
group and 4 in the placebo group, P=0.11). Three
infants in the placebo group received antibiotics,
as did one in the epinephrine group. No infants re-
ceived steroid therapy, and two in the placebo group
were treated with bronchodilators other than epi-
nephrine when their condition failed to improve.
Epinephrine had a significant effect on the heart
rate (Fig. 2). Sixty minutes after the last nebulization
treatment, the mean heart rate was 151 per minute
in the epinephrine group (95 percent confidence in-
terval, 147 to 156), as compared with 138 per min-
ute in the placebo group (95 percent confidence
interval, 134 to 142; P<0.001). In general, the res-
piratory rate 30 minutes after treatment tended to
be slightly higher (by about two breaths per minute)
in the epinephrine group than in the placebo group,
although the difference did not reach significance
(P=0.10 to P=0.68). There was little change in the
blood pressure of infants in the placebo group be-
fore and after treatment. In the epinephrine group,
there was an increase of about 5 mm Hg in both sys-
tolic and diastolic blood pressure 30 minutes after
treatment, which did not reach significance (P=0.06
 
* The data were obtained by parental report.
 
Table 2. Demographic Characteristics of the Infants at Admission 
to the Hospital.
Characteristic
Epinephrine 
(N=99)
Placebo 
(N=95) P Value
 
Mean (±SD) age — mo 4.52±3.01 4.35±2.95 0.70
Sex — M/F 60/39 61/34 0.66
Parental smoking — no. (%)
Both parents
One parent
Neither parent
22 (22.2)
30 (30.3)
47 (47.5)
19 (20.0)
26 (27.4)
50 (52.6)
0.50
Duration of coryza at admission
— no. (%)*
No coryza
<3 days
3–6 days
>6 days
13 (13.1)
30 (30.3)
44 (44.4)
12 (12.1)
15 (15.8)
33 (34.7)
37 (38.9)
10 (10.5)
0.35
Duration of wheezing at admission 
— no. (%)*
No wheezing
<3 days
3–6 days
>6 days
41 (41.4)
31 (31.3)
21 (21.2)
6 (6.1)
42 (44.2)
42 (44.2)
7 (7.4)
4 (4.2)
0.16
Severity of condition — no. (%)
Mild
Moderate
Severe
50 (50.5)
31 (31.3)
18 (18.2)
55 (57.9)
16 (16.8)
24 (25.3)
0.73
Positive for respiratory syncytial virus 
— no. (%)
70 (70.7) 59 (62.1) 0.23
Premature birth — no. (%) 13 (13.1) 15 (15.8) 0.68
Gestation — wk
Median
Range
35
27–36
35
25–36
Supplementary oxygen and intravenous 
feeding — no. (%)
No oxygen
Oxygen only
Oxygen and intravenous feeding
37 (37.4)
49 (49.5)
13 (13.1)
33 (34.7)
38 (40.0)
24 (25.3)
0.20
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to P=0.83). There was no significant difference be-
tween the groups in the change in the respiratory-
effort score from before to 60 minutes after each
treatment (P=0.18 to P=0.76), although 30 minutes
after the first treatment the epinephrine group had
a lower respiratory-effort score than the placebo
group (P=0.04) (Fig. 3). However, the epinephrine
group had slightly lower respiratory-effort scores
60 minutes after the final nebulization than the pla-
cebo group (2.44 [95 percent confidence interval,
1.97 to 2.92] vs. 3.35 [95 percent confidence inter-
val, 2.78 to 3.91], P=0.02).
Univariate analysis of the length of the hospital
stay and the time receiving supplemental oxygen
showed no significant differences between the re-
sponses to epinephrine at the various hospitals (P=
0.31 and P=0.66, respectively). Among patients
receiving epinephrine, there was no significant dif-
ference in the length of hospital stay between those
who were and those who were not positive for res-
piratory syncytial virus (P=0.11), or between those
with a first-degree relative who had a history of asth-
ma, eczema, or hay fever and those who did not have
such a family history (P=0.94).
The role of bronchodilators in acute bronchiolitis
is controversial, and the interpretation of many stud-
ies is complicated by the use of different definitions
of bronchiolitis, some of which apply the diagno-
sis to young children with recurrent wheezing ill-
ness that is more likely to be due to asthma. In ad-
dition, previous studies have had small numbers of
subjects, thus increasing the risks of a type I error.
This large, randomized, double-blind, controlled
trial of an inhaled bronchodilator with both 
 
a
 
-adre-
nergic and 
 
b
 
-adrenergic effects in infants with acute
bronchiolitis has clearly demonstrated that bron-
chodilators do not produce a clinically relevant im-
provement in clinical status or reduce the length
discussion
 
Figure 1. Mean Length of the Hospital Stay According to the Need for Supple-
mental Oxygen and Intravenous Fluids at Admission.
 
Error bars indicate 95 percent confidence intervals.
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Table 3. Length of the Hospital Stay, Time until the Infant Was Ready for Discharge, and Time Supplemental Oxygen 
Was Required, According to the Use or Nonuse of Supplemental Oxygen and Intravenous Fluids.
Variable
Epinephrine 
(N=99)
Placebo 
(N=95)
Ratio of Means of Epi-
nephrine and Placebo 
Groups P Value
 
mean (95% confidence interval)
 
Length of hospital stay (hr)
Overall
No oxygen
Oxygen only
Oxygen and intravenous fluids
58.8 (49.4–70.0)
25.8 (21.4–31.0)
85.9 (73.1–100.9)
147.4 (107.9–201.5)
69.5 (59.3–81.4)
33.5 (27.5–40.8)
98.0 (81.6–117.7)
109.6 (87.1–138.0)
0.85 (0.67–1.07)
0.77 (0.59–1.01)
0.88 (0.69–1.12)
1.34 (0.91–1.98)
0.16
0.06
0.29
0.14
Time until ready for discharge (hr)
Overall
No oxygen
Oxygen only
Oxygen and intravenous fluids
46.5 (38.3–56.5)
18.6 (15.2–22.9)
68.5 (57.5–81.7)
135.9 (96.6–191.3)
47.7 (39.0–58.3)
16.3 (13.1–20.3)
83.5 (68.4–102.0)
80.2 (62.0–103.5)
0.98 (0.74–1.29)
1.14 (0.85–1.55)
0.82 (0.63–1.07)
1.70 (1.11–2.60)
0.86
0.39
0.15
0.02
Time supplemental oxygen required (hr)
Overall
Oxygen only
Oxygen and intravenous fluids
54.0 (40.9–71.2)
43.6 (33.2–57.2)
121.0 (71.4–205.2)
58.8 (46.8–73.8)
56.1 (41.2–76.4)
63.2 (42.9–93.3)
0.92 (0.64–1.31)
0.78 (0.52–1.17)
1.91 (0.99–3.68)
0.64
0.22
0.06
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of the hospital stay in infants less than 12 months
of age with acute bronchiolitis.
Previous studies have found an improved short-
term clinical score after administration of an inhaled
bronchodilator. A substantial effect on the length of
the hospital stay and the time until the infant is
ready for discharge would require a sustained clini-
cal improvement. It could be argued that broncho-
dilator therapy, particularly with a short-acting bron-
chodilator, would not be likely to affect longer-term
outcomes unless therapy was given frequently or
had some beneficial effect on the underlying patho-
physiology. The 
 
a
 
-adrenergic effects of nebulized
epinephrine might reduce airway edema, which is
thought to have a role in the pathophysiology of
acute bronchiolitis. Transient reductions in edema
might improve pulmonary mechanics and clearance
of secretions, which could possibly have a longer-
lasting benefit. We thought that if nebulized epi-
nephrine resulted in any significant clinical im-
provement, albeit transient, it should be apparent
from our observations before and after the admin-
istration of the three doses over the nine hours of
repeated observations. No consistent statistically
significant change in the respiratory rate or respira-
tory-effort score was found from before each treat-
ment to after each treatment, although the infants
in the epinephrine group did have a lower respira-
tory-effort score after all three treatments. The im-
provement in the respiratory-effort score therefore
occurred between treatments rather than during
the observation period for each treatment. Thus,
either the improvement occurred several hours af-
ter the administration of epinephrine or it was not
related to the treatment at all. Although the respira-
tory-effort score was significantly lower in the epi-
nephrine group after the three treatments, the dif-
ference between the groups was small and clinically
trivial, and it was not associated with a shorter time
to readiness for discharge or a shorter hospital stay.
The randomization was not stratified according
to the severity of illness. More infants with moder-
ately severe illness were assigned to epinephrine
than to placebo, although the difference did not
reach statistical significance. This difference could
theoretically have moderated the effect of epineph-
rine in this group. However, more infants in the pla-
cebo group than in the epinephrine group required
both intravenous fluids and supplemental oxygen
(although the difference was not significant), a dif-
ference that could have increased the chances of
finding a significant difference between the groups
 
Figure 2. Mean Differences between the Heart Rate before Each Nebulization Treatment and Those 30 and 60 Minutes 
after Each Treatment.
 
Error bars indicate 95 percent confidence intervals.
No. of Patients
Epinephrine
Placebo
89 
87
93 
94
82 
89
87 
90
79 
84
78 
75
D
iff
er
en
ce
 b
et
w
ee
n 
th
e 
H
ea
rt
 R
at
e
be
fo
re
 E
ac
h 
Tr
ea
tm
en
t a
nd
 T
ha
t a
ft
er
Ea
ch
 T
re
at
m
en
t (
be
at
s/
m
in
)
1st Treatment 2nd Treatment 3rd Treatment
30
25
20
15
10
5
0
¡5
¡10
¡15
30 min 60 min 30 min 60 min 60 min30 min
P<0.001 P<0.001 P<0.001 P<0.001 P=0.02 P=0.01
PlaceboEpinephrine
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on April 2, 2017. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
349;1
 
www.nejm.org july 
 
3
 
, 
 
2003
 
The
 
 new england journal 
 
of
 
 medicine
 
34
 
in the length of the hospital stay and time until the
infant was ready for discharge.
Three different nebulizer systems were used in
this trial, all of which had similar minimal residual
volumes, with a respirable output under 5 µm rang-
ing from 76 to 85 percent. There were no significant
differences between hospitals in the response to epi-
nephrine or in the change in heart rate, suggesting
that enough epinephrine was administered at each
site to produce a measurable physiological change.
This would make it less likely that the lack of benefit
with nebulized epinephrine was due to differences
in the amounts administered by different nebulizer
systems.
Some trials of nebulized epinephrine have used
racemic epinephrine to reduce potential cardiac
effects, and an increase in heart rate has not been
consistently reported.
 
10,12,13
 
 In a small study, Krist-
jansson et al. found a small, clinically trivial increase
in systolic blood pressure immediately after and
45 minutes after the administration of nebulized
epinephrine but not 15, 30, or 60 minutes after the
drug was given.
 
12
 
 We report here a small but sta-
tistically significant increase in the heart rate, which
could theoretically increase oxygen-utilization costs
in vulnerable infants. Newth et al. described an in-
crease in oxygen utilization in rhesus monkeys
breathing 
 
b
 
2
 
-agonists that was blocked by the use
of propranolol, suggesting a 
 
b
 
-receptor–mediat-
ed mechanism.
 
17
 
 Among our patients assigned to
epinephrine who required both supplemental ox-
ygen and intravenous fluids, there was a significant
increase in the time until the infant was ready for
discharge and a trend toward an increase in the du-
ration of oxygen supplementation. Infants who re-
quired both supplemental oxygen and intravenous
fluids would be the most vulnerable and sickest pa-
tients, and increased oxygen utilization could lead
to prolonged use of supplemental oxygen and an
increase in the time until the infant was ready for
discharge.
The difference between the length of the hospi-
tal stay and the time until the infant was ready for
discharge was more than twice as great in the pla-
cebo group as in the epinephrine group for those
requiring no supplemental oxygen and for those re-
quiring both supplemental oxygen and intravenous
fluids. This may explain the trend toward a slightly
shorter hospital stay among infants in the epineph-
rine group who did not require supplemental oxy-
gen than among infants in the placebo group who
did not require supplemental oxygen, since there
 
Figure 3. Mean Differences between the Respiratory-Effort Score before Each Nebulization Treatment and Those 
30 and 60 Minutes after Each Treatment.
 
Error bars represent 95 percent confidence intervals. 
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was no such trend in the time until the infant was
ready for discharge.
Many health care professionals treat bronchioli-
tis with a bronchodilator just in case it is a first man-
ifestation of asthma. Although we could not deter-
mine which infants in this study would later have
asthma, we did find that a history of asthma, ecze-
ma, or hay fever in a first-degree relative did not af-
fect the response to nebulized epinephrine. This
would suggest that bronchodilators are not effec-
tive, even in children with acute bronchiolitis who
are at higher-than-average risk for asthma.
The need for supplemental oxygen, based on the
patient’s oxygen saturation while breathing room
air at admission, was highly predictive of the length
of the hospital stay. Similarly, oxygen saturation on
admission with acute asthma is highly predictive of
the severity of asthma.
 
18
 
 Oxygen saturation meas-
urements are usually performed in all infants ad-
mitted to the hospital with acute bronchiolitis and
could therefore easily be used for planning appro-
priate staffing and bed requirements for pediatric
wards.
This trial mirrors the reality of clinical practice
in both tertiary care and district hospitals, and our
results are therefore applicable to the majority of
hospitalized infants with acute bronchiolitis. Bron-
chodilators are widely used in many countries for
infants with bronchiolitis. Approximately 68 to 96
percent of infants with bronchiolitis are treated with
bronchodilators at tertiary pediatric centers in Can-
ada.
 
19,20
 
 In a European survey of 88 pediatric cen-
ters, 54 centers reported using bronchodilators
in all patients with bronchiolitis, and 15 centers
reported using bronchodilators only in high-risk
patients.
 
21
 
 In a survey of Australian pediatricians,
88 percent of respondents reported that they used
bronchodilators in some infants with bronchioli-
tis, and 21 percent that they used epinephrine in
such infants.
 
22
 
 Because there have been no previ-
ous large, randomized, controlled trials, the use of
bronchodilators for bronchiolitis has been contro-
versial, with multiple small studies reporting differ-
ent outcomes with different bronchodilators. The
evidence from this trial points clearly to a lack of
benefit, in either short-term or long-term clinically
relevant outcomes, of nebulized epinephrine in in-
fants hospitalized with acute bronchiolitis.
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